Cancer cell spheroids as a model to evaluate chemotherapy protocols

References

• World Cancer Report, Boyle P and Levin B, Editors. 2008, International Agency for Research on Cancer: Lyon.
   Google Scholar
• Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811 - 4; http://dx.doi.org/10.1038/nm0796-811; PMID: 8673929
   PubMed Web of Science ®Google Scholar
• Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878 - 84; PMID: 11895922
   PubMed Web of Science ®Google Scholar
• Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; 5:1703 - 7; PMID: 10430072
   PubMed Web of Science ®Google Scholar
• Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hematol 2000; 36:193 - 207; http://dx.doi.org/10.1016/S1040-8428(00)00086-X; PMID: 11033306
   PubMed Web of Science ®Google Scholar
• Mellor HR, Callaghan R. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemother Pharmacol 2011; 68:1179 - 90; http://dx.doi.org/10.1007/s00280-011-1598-8; PMID: 21400240
   PubMed Web of Science ®Google Scholar
• Marcucci F, Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012; 64:53 - 68; http://dx.doi.org/10.1016/j.addr.2011.09.007; PMID: 21983328
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Gao Y, Wientjes MG, Au JL. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond) 2011; 6:1605 - 20; http://dx.doi.org/10.2217/nnm.11.141; PMID: 22077464
   PubMed Web of Science ®Google Scholar
• Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr., Ruff LE, et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001; 159:2071 - 80; http://dx.doi.org/10.1016/S0002-9440(10)63058-1; PMID: 11733357
   PubMed Web of Science ®Google Scholar
• Yang TM, Barbone D, Fennell DA, Broaddus VC. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 2009; 41:14 - 23; http://dx.doi.org/10.1165/rcmb.2008-0320OC; PMID: 19097992
   PubMed Web of Science ®Google Scholar
• Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148:3 - 15; http://dx.doi.org/10.1016/j.jbiotec.2010.01.012; PMID: 20097238
   PubMed Web of Science ®Google Scholar
• Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007; 130:601 - 10; http://dx.doi.org/10.1016/j.cell.2007.08.006; PMID: 17719539
   PubMed Web of Science ®Google Scholar
• Kim TH, Mount CW, Gombotz WR, Pun SH. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 2010; 31:7386 - 97; http://dx.doi.org/10.1016/j.biomaterials.2010.06.004; PMID: 20598741
   PubMed Web of Science ®Google Scholar
• Gil-Cardeza ML, Villaverde MS, Fiszman GL, Altamirano NA, Cwirenbaum RA, Glikin GC, et al. Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Ther 2010; 17:26 - 36; http://dx.doi.org/10.1038/gt.2009.107; PMID: 19741734
   PubMed Web of Science ®Google Scholar
• Meng E, Taylor B, Ray A, Shevde LA, Rocconi RP. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol 2012; 124:598 - 605; http://dx.doi.org/10.1016/j.ygyno.2011.11.018; PMID: 22115853
   PubMed Web of Science ®Google Scholar
• Frassineti GL, Zoli W, Silvestro L, Serra P, Milandri C, Tienghi A, et al. Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol 1997; 24:Suppl 17 S17 - 9, S17-25; PMID: 9374087
   PubMedGoogle Scholar
• Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14:663 - 70; http://dx.doi.org/10.1177/1352458507085759; PMID: 18424479
   PubMed Web of Science ®Google Scholar
• Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer 2009; 12:153 - 7; http://dx.doi.org/10.1007/s10120-009-0517-8; PMID: 19890695
   PubMed Web of Science ®Google Scholar
• Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. Mol Pharm 2011; 8:833 - 40; http://dx.doi.org/10.1021/mp1004383; PMID: 21417439
   PubMed Web of Science ®Google Scholar
• Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999; 290:871 - 80; PMID: 10411604
   PubMed Web of Science ®Google Scholar
• Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VdelG, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334:1129 - 33; http://dx.doi.org/10.1126/science.1206727; PMID: 22033517
   PubMed Web of Science ®Google Scholar
• Davies CdeL, Lundstrøm LM, Frengen J, Eikenes L, Bruland S ØS, Kaalhus O, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 2004; 64:547 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-03-0576; PMID: 14744768
   PubMed Web of Science ®Google Scholar
• Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, et al. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer 2009; 125:2450 - 5; http://dx.doi.org/10.1002/ijc.24627; PMID: 19670329
   PubMed Web of Science ®Google Scholar
• Trédan O, Garbens AB, Lalani AS, Tannock IF. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 2009; 69:940 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-0676; PMID: 19176397
   PubMed Web of Science ®Google Scholar
• Dunkern TR, Mueller-Klieser W. Quantification of apoptosis induction by doxorubicin in three types of human mammary carcinoma spheroids. Anticancer Res 1999; 19:4B 3141 - 6; PMID: 10652603
   PubMed Web of Science ®Google Scholar
• Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res 2002; 93:1145 - 53; http://dx.doi.org/10.1111/j.1349-7006.2002.tb01217.x; PMID: 12417045
   PubMedGoogle Scholar
• Dimas K, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, et al. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. Biomed Pharmacother 2006; 60:127 - 33; http://dx.doi.org/10.1016/j.biopha.2006.01.003; PMID: 16527443
   PubMed Web of Science ®Google Scholar
• Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia 2002; 16:1808 - 17; http://dx.doi.org/10.1038/sj.leu.2402573; PMID: 12200697
   PubMed Web of Science ®Google Scholar
• Son K, Huang L. Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci U S A 1994; 91:12669 - 72; http://dx.doi.org/10.1073/pnas.91.26.12669; PMID: 7809098
   PubMed Web of Science ®Google Scholar
• Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004; 10:1633 - 44; http://dx.doi.org/10.1158/1078-0432.CCR-0829-3; PMID: 15014014
   PubMed Web of Science ®Google Scholar
• Kohno N, Ohnuma T, Kaneko M, Holland JF. Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. Br J Cancer 1988; 58:330 - 4; http://dx.doi.org/10.1038/bjc.1988.213; PMID: 3179185
   PubMed Web of Science ®Google Scholar
• Leonard RC, Cornbleet MA, Kaye SB, Soukop M, White G, Hutcheon AW, et al. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 1987; 5:1056 - 63; PMID: 3298559
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharm Sci 2012; 45:388 - 98; http://dx.doi.org/10.1016/j.ejps.2011.09.006; PMID: 21933707
   PubMed Web of Science ®Google Scholar
• Bontenbal M, Planting AS, Rodenburg CJ, Dees A, Verweij J, Bartels CC, et al. Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer. Breast Cancer Res Treat 1992; 21:133 - 8; http://dx.doi.org/10.1007/BF01836959; PMID: 1627816
   PubMed Web of Science ®Google Scholar
• ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009; 15:1973 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-08-2392; PMID: 19276264
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003; 100:6039 - 44; http://dx.doi.org/10.1073/pnas.0931428100; PMID: 12716967
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13:2688 - 99; PMID: 7595726
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006; 91:133 - 6; PMID: 16434383
   PubMed Web of Science ®Google Scholar
• Toh YM, Li TK. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin Cancer Res 2011; 17:5026 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-11-0235; PMID: 21653687
   PubMed Web of Science ®Google Scholar
• Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58:776 - 84; http://dx.doi.org/10.1007/s00280-006-0224-7; PMID: 16532342
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Ho B, Zheng M, Magis A, Ostrov D, Cance W. Mitoxantrone Targets The ATP-Binding Site Of FAK, Binds The FAK Kinase Domain And Decreases FAK, Pyk-2, C-Src, And IGF-1R, Pyk-2 In Vitro Kinase Activities. Anticancer Agents Med Chem 2012; PMID: 22292772
   PubMed Web of Science ®Google Scholar
• Chen YY, Wang ZX, Chang PA, Li JJ, Pan F, Yang L, et al. Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance. Cancer Sci 2009; 100:1708 - 13; http://dx.doi.org/10.1111/j.1349-7006.2009.01217.x; PMID: 19500106
   PubMed Web of Science ®Google Scholar
• Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 2007; 322:80 - 8; http://dx.doi.org/10.1124/jpet.107.121632; PMID: 17420296
   PubMed Web of Science ®Google Scholar
• Dehghani L, Karbalaei KH, Nematollahi M, Nasr Esfahani MH, Baharvand H. Dexamethasone reduces doxorubicin-induced oxidative stress and caspase 3 activity in MESC-derived pure cardiomyocytes. Cell Journal (Yakhteh), 2011; 13(Suppl. 3 (7th Congress on Stem Cell Biology and Technology)): 28-29.
   Google Scholar
• Chlebowski RT, Bull F, Irwin L, Pugh R, Weiner JM, Bateman JR. Doxorubicin and methotrexate on a weekly schedule in patients with sarcomas. Oncology 1987; 44:210 - 3; http://dx.doi.org/10.1159/000226479; PMID: 3475644
   PubMed Web of Science ®Google Scholar
• Muro H, Acuña LR, Castagnari A, Blajman C, Schmilovich A, Hidalgo A, et al. Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer. Cancer Treat Rep 1986; 70:1333 - 4; PMID: 3768875
   PubMedGoogle Scholar
• Hrushesky WJ, Bjarnason GA. Circadian cancer therapy. J Clin Oncol 1993; 11:1403 - 17; PMID: 8315438
   PubMed Web of Science ®Google Scholar
• Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361:1662 - 70; http://dx.doi.org/10.1056/NEJMoa0810613; PMID: 19846851
   PubMed Web of Science ®Google Scholar
• Iakoubov LZ, Torchilin VP. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect Prev 1998; 22:470 - 5; http://dx.doi.org/10.1046/j.1525-1500.1998.00055.x; PMID: 9727629
   PubMedGoogle Scholar
• Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 2007; 99:1004 - 15; http://dx.doi.org/10.1093/jnci/djm027; PMID: 17596572
   PubMed Web of Science ®Google Scholar
• Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 2004; 98:415 - 26; http://dx.doi.org/10.1016/j.jconrel.2004.06.003; PMID: 15312997
   PubMed Web of Science ®Google Scholar
• Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007; 6:2505 - 14; http://dx.doi.org/10.1158/1535-7163.MCT-06-0698; PMID: 17766839
   PubMed Web of Science ®Google Scholar